Page last updated: 2024-10-30

losartan and Anemia

losartan has been researched along with Anemia in 12 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.

Research Excerpts

ExcerptRelevanceReference
"Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients."7.73Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005)
"High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications."5.10The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003)
"Losartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients."3.73Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. ( Cift, A; Dilek, K; Ersoy, A; Ersoy, C; Kahvecioglu, S, 2005)
"Arterial hypertension significantly decreased after the introduction of losartan (p = 0."3.72Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. ( Anaya, F; Campistol, JM; Del Castillo, D; Esforzado, N; Iñigo, P; Navarro, MD; Oppenheimer, F; Saracho, R, 2003)
"Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)."2.71Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004)
"Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate."2.71Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (33.33)18.2507
2000's7 (58.33)29.6817
2010's0 (0.00)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Aung, TKK1
Chuah, TY1
Chua, MWJ1
Odabas, AR1
Cetinkaya, R1
Selcuk, Y1
Keles, S1
Bilen, H1
Iñigo, P1
Campistol, JM1
Saracho, R1
Del Castillo, D1
Anaya, F1
Esforzado, N1
Navarro, MD1
Oppenheimer, F1
Mohanram, A2
Zhang, Z2
Shahinfar, S2
Keane, WF1
Brenner, BM1
Toto, RD2
Ichihara, A1
Hayashi, M1
Kaneshiro, Y1
Takemitsu, T1
Homma, K1
Kanno, Y1
Yoshizawa, M1
Furukawa, T1
Takenaka, T1
Saruta, T1
Ersoy, A1
Kahvecioglu, S1
Ersoy, C1
Cift, A1
Dilek, K1
Lyle, PA1
Schwarzbeck, A1
Wittenmeier, KW1
Hällfritzsch, U1
Lang, SM2
Schiffl, H2
Kato, A1
Takita, T1
Furuhashi, M1
Takahashi, T1
Maruyama, Y1
Hishida, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347]Phase 31,513 participants (Actual)Interventional1996-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

7 trials available for losartan and Anemia

ArticleYear
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
    Panminerva medica, 2003, Volume: 45, Issue:1

    Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response

2003
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
    Kidney international, 2004, Volume: 66, Issue:3

    Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr

2004
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5

    Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo

2005
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
    Kidney international, 2008, Volume: 73, Issue:5

    Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropat

2008
Losartan and anaemia of end-stage renal disease.
    Lancet (London, England), 1998, Nov-21, Volume: 352, Issue:9141

    Topics: Anemia; Antihypertensive Agents; Erythropoietin; Humans; Hypertension; Kidney Failure, Chronic; Losa

1998
Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease.
    Nephron, 1999, Volume: 81, Issue:1

    Topics: Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

1999
No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis.
    Nephron, 2000, Volume: 86, Issue:4

    Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Interactions; Erythr

2000

Other Studies

5 other studies available for losartan and Anemia

ArticleYear
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
    The American journal of medicine, 2021, Volume: 134, Issue:11

    Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes

2021
Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study.
    Nephron. Clinical practice, 2003, Volume: 95, Issue:3

    Topics: Anemia; Antihypertensive Agents; Cough; Creatinine; Female; Follow-Up Studies; Humans; Hyperkalemia;

2003
Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
    Transplantation proceedings, 2005, Volume: 37, Issue:5

    Topics: Adult; Anemia; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers; Creatinine; Eryth

2005
Anaemia in dialysis patients as a side-effect of sartanes.
    Lancet (London, England), 1998, Jul-25, Volume: 352, Issue:9124

    Topics: Anemia; Antihypertensive Agents; Biphenyl Compounds; Hemoglobins; Humans; Irbesartan; Kidney Transpl

1998
Anaemia due to ACE inhibitors and losartan in patients with renal failure.
    Prescrire international, 1999, Volume: 8, Issue:44

    Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trial

1999